Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice
暂无分享,去创建一个
Hitoshi Sato | Hirofumi Fujii | Kenji Kawada | Hitoshi Sato | K. Itoh | Y. Sasaki | T. Igarashi | H. Fujii | M. Tahara | H. Minami | Toshiaki Saeki | Hironobu Minami | Yasutsuna Sasaki | T. Saeki | K. Kawada | Makoto Tahara | Kazuhiro Ozawa | Tadahiko Igarashi | Kuniaki Itoh | Kazuhiro Ozawa
[1] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Alan Gordon,et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.
[3] S. Clarke,et al. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. , 2004, British journal of clinical pharmacology.
[4] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[5] F. Holmes,et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L Aarons,et al. Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.
[7] E. Ette,et al. Stability and Performance of a Population Pharmacokinetic Model , 1997, Journal of clinical pharmacology.
[8] G. Montay,et al. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. , 1992, Journal of chromatography.
[9] J. Ajani,et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .
[10] Paul J. Williams,et al. The Role of Population Pharmacokinetics in Drug Development in Light of the Food and Drug Administration’s ‘Guidance for Industry: Population Pharmacokinetics’ , 2000, Clinical pharmacokinetics.
[11] I. Hyodo,et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] T. Schnider,et al. Expanding clinical applications of population pharmacodynamic modelling. , 1998, British journal of clinical pharmacology.
[13] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[15] M. Hidalgo,et al. Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue , 2006, Clinical Cancer Research.
[16] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[17] A. Racine‐Poon,et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. , 2005, British journal of clinical pharmacology.
[18] K. Syrigos,et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Busse,et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] David Hinkley,et al. Bootstrap Methods: Another Look at the Jackknife , 2008 .
[21] V. Georgoulias,et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Samara,et al. Role of Population Pharmacokinetics in Drug Development , 1997, Clinical pharmacokinetics.
[23] R. Schilsky,et al. Pharmacodynamics in cancer therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Klein,et al. Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.
[25] J. Verweij,et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Wanders,et al. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Robert Tibshirani,et al. Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .
[28] H. Ohmatsu,et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Dorner,et al. Population Pharmacokinetics of CCI‐779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer , 2005, Clinical pharmacology and therapeutics.